CrossRelay is a scalable human cDC1-like APC platform for antigen presentation and CD8-directed discovery
CrossRelay is a scalable human cDC1-like APC platform designed to support antigen presentation studies, cross-presentation-relevant workflows, immune assay development, and CD8-directed discovery.
Built on a renewable human cDC1-like APC foundation, the platform combines scalable manufacture with biologically relevant antigen handling and CD8 T-cell priming utility across discovery-stage programs.
What is CrossRelay?
A renewable APC starting point
CrossRelay is built around a renewable APC foundation rather than repeated dependence on short-lived donor-derived preparations. That matters when studies require scale, consistency, and repeatability.
Built around cDC1-like relevance
The platform is built around cDC1-like functional orientation because that biology is closely linked to antigen presentation, cross-presentation, and productive CD8-directed immune interrogation.
Intended for real discovery workflows
CrossRelay supports target assessment, immune assay development, ex vivo T-cell studies, and broader translational questions where APC performance can determine study value.
What underlies CrossRelay?
A renewable human cDC1-like APC foundation
The platform foundation provides a cell system with features relevant to antigen uptake, antigen presentation, cross-presentation-relevant study design, and CD8-directed immune priming.
Its cDC1-like orientation is informed by biology associated with IRF8, BATF3, XCR1, CADM1, and ID2, providing a scientific framework relevant to antigen presentation and CD8-directed immune studies.
A scalable APC foundation inside the platform
This renewable APC foundation is what makes the broader platform useful. It helps make difficult antigen-presentation questions more tractable in discovery workflows.
Within CrossRelay, that foundation links biological relevance with scalable platform design so that APC-dependent studies can be run with greater consistency and operational flexibility.
cDC1-like orientation
CrossRelay is described as cDC1-like because that framing aligns with the biology most relevant to cross-presentation and CD8-directed immune work.
Renewable and repeatable
The value of the platform increases when the APC foundation can be renewed, scaled, and used reproducibly across multiple programs and study cycles.
Scientifically grounded
CrossRelay is described as a cDC1-like APC platform for discovery use. The language remains specific to antigen presentation, CD8-directed immune studies, and APC-enabled workflows.
How the platform can assist immunotherapy discovery
Antigen and target assessment
The platform can support studies that ask whether a candidate antigen, construct, or payload is being handled in a way that is relevant to downstream CD8-directed immunity.
Immune assay development
A stronger APC foundation can make assay outputs more interpretable by reducing variability introduced by weak or inconsistent antigen-presenting inputs.
Ex vivo CD8 workflows
CrossRelay is designed to support ex vivo workflows where APC quality influences priming, expansion, activation readouts, or comparative study design.
Translational platform building
The same APC foundation can support broader translational uses such as workflow standardization, potency-oriented benchmarking, and APC-enabled program development.
Why this matters in immunotherapy
- Primary APC workflows can be biologically valuable but operationally variable.
- Cross-presentation-relevant studies are often limited by APC quality rather than by the target concept alone.
- Discovery teams need systems that can handle peptide, encoded antigen, and more complex antigen formats in a repeatable framework.
- A scalable APC foundation can shorten iteration cycles in target validation and immune assay refinement.
How CrossRelay supports immunotherapy discovery
- CrossRelay provides a scalable human cDC1-like APC platform for antigen presentation studies relevant to downstream CD8 immunity.
- Built on a renewable human cDC1-like APC foundation, the platform supports more consistent evaluation of peptide, encoded, and complex antigen formats in APC-enabled workflows.
- CrossRelay can help teams refine assay design, compare target concepts, and generate biologically relevant immune readouts for immunotherapy discovery.
- By combining renewable cell supply with cDC1-like functionality, CrossRelay supports iterative target validation, immune assay development, and translational study planning.
Why the platform is differentiated
CrossRelay is built on a renewable human cDC1-like APC foundation designed for scalable manufacture and repeatable antigen-presentation workflows.
The platform supports antigen assessment, assay refinement, ex vivo T-cell studies, and translational immune workflow design rather than a single narrow use case.
Where appropriate, the platform can be described with approved statements such as: a predominant antigen-specific CD8 T-cell population is generated in two weeks, and over 90% antigen expression can be achieved in cDC1-like APC.
Conventional primary APC workflows can be limited by donor variability, finite scale, or unstable functional windows. CrossRelay addresses those constraints with a renewable, scalable APC foundation for discovery use.
Explore how CrossRelay can support APC-dependent discovery
CrossRelay gives discovery teams a more consistent human APC foundation for antigen presentation studies, assay development, and CD8-directed immunotherapy workflows.